ArticleScientific reports2025
An integrative computational approach for identification of NLRP3 inhibitors through machine learning, docking, dynamics and DFT analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Disrupting virulence: in silico discovery of MexL inhibitors to block pyocyanin biosynthesis in Pseudomonas aeruginosa.Archives of microbiology · 2026Article
- Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates.Frontiers in pharmacology · 2026Review
- Structural dynamics, pathogenic mechanisms, and therapeutic targeting of the NLRP3 inflammasome in lupus nephritis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Neuroinflammation, mediated by NLR family pyrin domain containing 3 (NLRP3) inflammasome, plays a crucial role in the development of many central nervous system (CNS) diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. Despite extensive efforts, there are no clinically approved NLRP3 inhibitors due to issues like poor selectivity, undesirable drug-like properties, and safety concerns. In this study, a machine learning-based virtual screening strategy was used to identify phytochemicals that inhibit the NLRP3 NACHT domain, a key region involved in ATP-driven oligomerization and inflammasome activation. A carefully curated set of 1,956 active compounds and 5,476 inactive ones was employed to train various classifiers, with the Random Forest model demonstrating the best predictive performance (AUC = 0.83). This enhanced model was applied to analyze the MPD3 phytochemical library, resulting in 183 drug-like candidates. Molecular docking revealed that PubChem 348,482, ZINC14583344, and PubChem 11,027,076 showed excellent binding affinities (-10.6 to - 11.3 kcal/mol), forming strong interactions with key residues (Ala228, Arg578, Glu629) known to influence NLRP3 conformational dynamics. ADMET analysis confirmed favorable pharmacokinetic and safety profiles, while molecular dynamics simulations over more than 100 ns verified the stability of the protein-ligand complexes through consistent RMSD, RMSF, and hydrogen bonding patterns of ZINC14583344. MM-GBSA free energy calculations further identified ZINC14583344 (-23.99 kcal/mol) as the most promising candidate. Additionally, Density Functional Theory (DFT) analysis indicated that ZINC14583344 has a smaller HOMO-LUMO gap, higher softness, and greater electrophilicity, suggesting superior reactivity and receptor binding flexibility. Conversely, PubChem 348,482 displayed a higher dipole moment and nucleophilicity, indicating stronger hydrogen bonding and electrostatic interactions with polar residues. Collectively, these findings highlight ZINC14583344 and PubChem 348,482 as promising scaffolds for developing selective NLRP3 inhibitors, providing a basis for therapeutic strategies against neuroinflammation-related CNS disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.